Submit Feedback
Recent searches
    Trending searches
    +

    Moderna Competitors & Alternatives

    Moderna competitors and alternatives

    Jump
    Company
    Ticker
    MRNA
    Headquarter
    Cambridge ,MA
    US
    CEO
    Mr. Stephane Bancel
    Industry
    Biotechnology
    Stock Price
    Stock Price
    Market Cap
    $16.23B
    Employees
    Years
    • 2021
    • 2022
    • 2023
    Employees
    • 2.70K
    • 3.90K
    • 5.60K
    Y/Y
    107.69%
    44.44%
    43.59%

    Income Statement

    Revenue
    Years
    • 2021
    • 2022
    • 2023
    Revenue
    • $17.74B
    • $19.26B
    • $6.85B
    Y/Y
    6361.44%
    8.61%
    64.45%
    Revenue by Products / Services
    Revenue by Geography
    Research and Development
    Years
    • 2021
    • 2022
    • 2023
    Research and Development
    • $1.99B
    • $3.30B
    • $4.85B
    Y/Y
    45.29%
    65.49%
    47.04%
    Operating Income
    Years
    • 2021
    • 2022
    • 2023
    Operating Income
    • $13.30B
    • $9.42B
    • -$4.24B
    Y/Y
    1842.27%
    29.15%
    145%
    Tax Rate (%)
    Years
    • 2021
    • 2022
    • 2023
    Tax Rate (%)
    • 8.00%
    • 13.00%
    • -20.00%
    Y/Y
    2497.06%
    55.46%
    254.54%
    Net Income
    Years
    • 2021
    • 2022
    • 2023
    Net Income
    • $12.20B
    • $8.36B
    • -$4.71B
    Y/Y
    1733.33%
    31.47%
    156.37%

    Assets & Liabilities | Cash Flow

    Total Assets
    Years
    • 2021
    • 2022
    • 2023
    Total Assets
    • $24.67B
    • $25.86B
    • $18.43B
    Y/Y
    236.23%
    4.82%
    28.74%
    Total Liabilities
    Years
    • 2021
    • 2022
    • 2023
    Total Liabilities
    • $10.52B
    • $6.74B
    • $4.57B
    Y/Y
    120.35%
    36%
    32.12%
    Capital Expenditures (Capex)
    Years
    • 2021
    • 2022
    • 2023
    Capital Expenditures (Capex)
    • -$284.00M
    • -$400.00M
    • -$707.00M
    Y/Y
    321.07%
    40.85%
    76.75%

    Profitability

    Operating Income Margin (%)
    Years
    • 2021
    • 2022
    • 2023
    Operating Income Margin (%)
    • 74.97%
    • 48.90%
    • -61.90%
    Y/Y
    126.97%
    34.77%
    226.58%
    Net Income Margin (%)
    Years
    • 2021
    • 2022
    • 2023
    Net Income Margin (%)
    • 68.80%
    • 43.41%
    • -68.84%
    Y/Y
    125.28%
    36.9%
    258.58%
    EBITDA
    Years
    • 2021
    • 2022
    • 2023
    EBITDA
    • $13.53B
    • $9.77B
    • -$-3.28B
    Y/Y
    1948.09%
    27.79%
    133.61%
    Free Cash Flow (FCF)
    Years
    • 2021
    • 2022
    • 2023
    Free Cash Flow (FCF)
    • $13.34B
    • $4.58B
    • -$3.83B
    Y/Y
    580.57%
    65.65%
    183.5%

    Ratios

    Return on Equity (ROE)
    Years
    • 2021
    • 2022
    • 2023
    Return on Equity (ROE)
    • 86.26%
    • 43.73%
    • -34.03%
    Y/Y
    395.71%
    49.3%
    177.82%
    Return on Assets (ROA)
    Years
    • 2021
    • 2022
    • 2023
    Return on Assets (ROA)
    • 49.46%
    • 32.34%
    • -25.58%
    Y/Y
    585.85%
    34.61%
    179.1%
    Debt to Equity
    Years
    • 2021
    • 2022
    • 2023
    Debt to Equity
    • 6.19%
    • 0.25%
    • 0.00%
    Y/Y
    100%
    95.96%
    100%

    Valuation

    Enterprise Value
    Years
    • 2021
    • 2022
    • 2023
    Enterprise value
    • $95.51B
    • $67.57B
    • $36.33B
    Y/Y
    156.64%
    29.26%
    46.24%
    Enterprise value to Revenue
    Years
    • 2021
    • 2022
    • 2023
    Enterprise value to Revenue
    • 5.38
    • 3.51
    • 5.30
    Y/Y
    96.03%
    34.86%
    51.24%
    Enterprise value to EBITDA
    Years
    • 2021
    • 2022
    • 2023
    Enterprise value to EBITDA
    • 7.06
    • 6.92
    • -11.06
    Y/Y
    113.89%
    2.02%
    259.97%

    Related company

    Submit feedback to Bullfincher